Monoclonal antibodies in neuro-oncology

References

• Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon?? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231 - 239
   PubMed Web of Science ®Google Scholar
• Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35:121 - 136
   PubMed Web of Science ®Google Scholar
• Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7:153
   PubMed Web of Science ®Google Scholar
• Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?. Anticancer Agents Med Chem 2008; 8:488 - 496
   PubMed Web of Science ®Google Scholar
• Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 2007; 33:161 - 176
   PubMed Web of Science ®Google Scholar
• Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14:6697 - 6703
   PubMed Web of Science ®Google Scholar
• Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?. Eur J Cancer 2008; 44:2350 - 2356
   PubMed Web of Science ®Google Scholar
• Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12:443 - 450
   PubMed Web of Science ®Google Scholar
• Kaal EC, Vecht CJ. CNS complications of breast cancer: current and emerging treatment options. CNS Drugs 2007; 21:559 - 579
   PubMed Web of Science ®Google Scholar
• Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45:196 - 201
   PubMed Web of Science ®Google Scholar
• Azar JM, Schneider BP, Einhorn LH. Is the blood-brain barrier relevant in metastatic germ cell tumor?. Int J Radiat Oncol Biol Phys 2007; 69:163 - 166
   PubMed Web of Science ®Google Scholar
• Lampson LA. Targeted therapy for neuro-oncology: reviewing the menu. Drug Discov Today 2009; 14:185 - 191
   PubMed Web of Science ®Google Scholar
• Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 2009; 29:5171 - 5184
   PubMed Web of Science ®Google Scholar
• Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007; 6:1909 - 1919
   PubMed Web of Science ®Google Scholar
• Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009; 9:444
   PubMed Web of Science ®Google Scholar
• Aho R, Ekfors T, Haltia M, Kalimo H. Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme. Acta Neuropathol 1993; 86:71 - 76
   PubMed Web of Science ®Google Scholar
• Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer 2007; 43:1141 - 1152
   PubMed Web of Science ®Google Scholar
• Mohile NA, Abrey LE. Primary central nervous system lymphoma. Semin Radiat Oncol 2007; 17:223 - 229
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007; 63:257 - 268
   PubMed Web of Science ®Google Scholar
• Takahashi JA, Llena JF, Hirano A. Pathology of cerebral metastases. Neurosurg Clin N Am 1996; 7:345 - 367
   PubMed Web of Science ®Google Scholar
• Poulsen HS. Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009; 48:52 - 58
   PubMed Web of Science ®Google Scholar
• Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009; 91:329 - 336
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008; 13:739 - 750
   PubMed Web of Science ®Google Scholar
• Siu D. Cancer therapy using tumor-associated antigens to reduce side effects. Clin Exp Med 2009; 9:181 - 198
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13:725 - 732
   PubMed Web of Science ®Google Scholar
• Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109:170 - 179
   PubMed Web of Science ®Google Scholar
• Lampson LA. New animal models to probe brain tumor biology, therapy and immunotherapy: advantages and remaining concerns. J Neurooncol 2001; 53:275 - 287
   PubMed Web of Science ®Google Scholar
• Lampson LA. Martinez R. Beyond new models: What else we need. Animal Models of Brain Tumors Humana In press
   Google Scholar
• Lampson L. Kennet R, et al. Molecular bases of neuronal individuality: Lessons from anatomical and biochemical studies with monoclonal antibodies. Monoclonal Antibodies and Functional Cell Lines: Progress and Applications 1984; Plenum Press 153 - 189
   Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83 - 117
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2009; 23:137 - 142
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008; 70:2252 - 2260
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005; 11:986 - 991
   PubMed Web of Science ®Google Scholar
• Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 2007; 81:139 - 148
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007; 13:3545 - 3558
   PubMed Web of Science ®Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27:5838 - 5847
   PubMed Web of Science ®Google Scholar
• Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. mAbs 2009; 1:222 - 229
   PubMed Web of Science ®Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007; 233 - 242
   PubMedGoogle Scholar
• Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5:611 - 615
   PubMed Web of Science ®Google Scholar
• Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007; 12:1084 - 1095
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715 - 725
   PubMed Web of Science ®Google Scholar
• Ward ES, Ober RJ. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 2009; 103:77 - 115
   PubMed Web of Science ®Google Scholar
• Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28:4947 - 4967
   PubMed Web of Science ®Google Scholar
• Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment and Trojan horses. Clin Cancer Res 2007; 13:1663 - 1674
   PubMed Web of Science ®Google Scholar
• Saunders NR, Ek CJ, Habgood MD. Dziegielewska KM, Barriers in the brain: a renaissance?. Trends Neurosci 2008; 31:279 - 286
   PubMed Web of Science ®Google Scholar
• Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy?. Pharmacol Ther 2009; 123:80 - 104
   PubMed Web of Science ®Google Scholar
• Choi YK, Kim KW. Blood-neural barrier: its diversity and coordinated cell-to-cell communication. BMB Rep 2008; 41:345 - 352
   PubMed Web of Science ®Google Scholar
• Kuo TT, de Muinck EJ, Claypool SM, Yoshida M, Nagaishi T, Aveson VG, et al. N-glycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. J Biol Chem 2009; 284:8292 - 8300
   PubMed Web of Science ®Google Scholar
• Hermann DM. Biodistribution processes as underestimated confounders in translational stroke research. Curr Med Chem 2007; 14:3179 - 3184
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007; 25:2306 - 2312
   PubMed Web of Science ®Google Scholar
• Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008; 10:166 - 177
   PubMed Web of Science ®Google Scholar
• Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 2007; 48:1712 - 1720
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Erkutlu I, Kilciksiz S, Pehlivan M, Okan V, Alptekin M, et al. Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases. Hematology 2008; 13:107 - 113
   PubMed Web of Science ®Google Scholar
• Kim WY, Lee HY. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J 2009; 276:4653 - 4664
   PubMed Web of Science ®Google Scholar
• Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009; 75:1148 - 1154
   PubMed Web of Science ®Google Scholar
• Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009; 94:63 - 68
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306 - 314
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25:4730 - 4735
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676 - 688
   PubMed Web of Science ®Google Scholar
• Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev 2007; 26:635 - 643
   PubMed Web of Science ®Google Scholar
• Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459:1005 - 1009
   PubMed Web of Science ®Google Scholar
• Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?. APMIS 2008; 116:552 - 568
   PubMed Web of Science ®Google Scholar
• Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007; 85:311 - 317
   PubMed Web of Science ®Google Scholar
• Bravo Marques JM. Treatment of brain metastases in patients with HER2+ breast cancer. Adv Ther 2009; 26:18 - 26
   Google Scholar
• Church DN, Bahl A, Jones A, Price CG. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab—a case report. J Neurooncol 2006; 79:289 - 292
   PubMed Web of Science ®Google Scholar
• Metro G, Sperduti I, Russillo M, Milella M, Cognetti F, Fabi A. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007; 12:1467 - 1469
   PubMed Web of Science ®Google Scholar
• Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009; 20:56 - 62
   PubMed Web of Science ®Google Scholar
• Hong SJ, Kim JS, Chang JH, Kim KM, Kim SJ, Lee HW, et al. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J 2009; 50:280 - 283
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101:466 - 468
   PubMed Web of Science ®Google Scholar
• Chow SC, Chang M. Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 2008; 3:11
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Engineered CH2 domains (nanoantibodies). mAbs 2009; 1:26 - 28
   PubMed Web of Science ®Google Scholar
• Lampson L, Tripp C. Antibody-secreting cells to deliver antibody against brain metastases. J Clinical Oncology 2007; 25:3047
   Google Scholar